Yahoo Finance

SOFIE Biosciences Announces First Patient Dosed in [18F]FAPI-74 Phase 3 Study

DULLES, Va., Dec. 29, 2025 /PRNewswire/ -- SOFIE Biosciences, an established U.S. manufacturer and developer of radiopharmaceuticals, today announced that the first patient has been dosed in one of ...
Pharmabiz

SOFIE Biosciences doses first patient dosed in phase 3 trials of [18F]FAPI-74, a fluorine-18 labelled radiopharmaceutical targeting FAP for patients with GI cancers

SOFIE Biosciences, an established US manufacturer and developer of radiopharmaceuticals, announced that the first patient has been dosed in one of its two phase 3 clinical trials evaluating ...
Nasdaq

Y-mAbs Hosts Virtual Radiopharmaceutical R&D Update Highlighting Clinical Progress and Expanded Pipeline

PRINCETON, N.J., May 28, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and ...
Yahoo Finance

SOFIE Biosciences Announces First Patient Dosed in [18F]FAPI-74 Phase 3 Study for Pancreatic Cancer

DULLES, Va., Feb. 11, 2026 /PRNewswire/ -- SOFIE Biosciences, an established U.S. manufacturer and developer of radiopharmaceuticals, today announced that the first patient has been dosed in the ...